Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 3, 2016, Pages

  Shepherd, Andrew Rh ^a,b   Shepherd, Emily ^c   Brook, Nicholas R ^a,b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCG VACCINE;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; DISEASE SPECIFIC SURVIVAL; DRUG DOSE COMPARISON; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; NON MUSCLE INVASIVE BLADDER CANCER; OUTCOME ASSESSMENT; QUALITY OF LIFE; SYSTEMATIC REVIEW; TRANSURETHRAL RESECTION;

EID: 84961888038     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD012112     Document Type: Article

References (48)

1. Babjuk M, Böhle A, Burger M, Compérat E, Kaasinen E, Palou J, et al. Guidelines on non-muscle-invasive bladder cancer (Ta, T1 and CIS): update 2014. European Association of Urology; 2014 April.
2. Biot C, Rentsch CA, Gsponer JR, Birkhäuser FD, Jusforgues-Saklani H, Lemaître F, et al. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Science Translational Medicine 2012;4(137):137ra72. [DOI: 10.1126/scitranslmed.3003586]
3. Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. European Urology 2002;41(5):523-31.
4. Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. Journal of Urology 2011;186(6):2158-67.
5. Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, et al. Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. European Urology 2014;65(1):69-76.
6. Brennan P, Bogillot O, Cordier S, Greiser E, Schill W, Vineis P, et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. International Journal of Cancer. Journal International du Cancer 2000;86(2):289-94.
7. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. European Urology 2013;63(2):234-41.
8. Cancer Research UK. Bladder cancer key facts. http://publications.cancerresearchuk.org/downloads/Product/CS_KF_BLADDER.pdf (accessed 30 December 2014).
9. Chu H, Wang M, Zhang Z. Bladder cancer epidemiology and genetic susceptibility. Journal of Biomedical Research 2013;27(3):170-8.
10. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
11. Thomson Reuters. EndNote. Version X7.5.1. Thomson Reuters, 2016.
12. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr (accessed 1 January 2015).
13. Ferrantini M, Capone I, Belardelli F. Interferon-α and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 2007;89(6-7):884-93.
14. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA 2011;306(7):737-45.
15. McMaster University. GRADEpro GDT: GRADEpro Guideline Development Tool. McMaster University, 2015 (developed by Evidence Prime, Inc.). Available from www.gradepro.org.
16. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Schünemann HJ, et al. GRADE: what is "quality of evidence" and why is it important to clinicians?. BMJ (Clinical Research Ed.) 2008;336(7651):995-8.
17. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94.
18. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
19. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical Research Ed.) 2003;327(7414):557-60.
20. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
21. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
22. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
23. Joudi FN, Smith BJ, O'Donnell MA, National BCG-Interferon Phase 2 Investigator Group. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon α-2B for reducing recurrence of superficial bladder cancer. Urologic Oncology 2006;24(4):344-8.
24. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66(6 Suppl 1):4-34.
25. Lam JS, Benson MC, O'Donnell MA, Sawczuk A, Gavazzi A, Wechsler MH, et al. Bacillus calmette-guérin plus interferon-α2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urologic Oncology 2003;21(5):354-60.
26. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009;6(7):e1000100.
27. Lopez-Beltran A, Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. European Urology 2004;46(2):170-6.
28. Luo Y, Chen X, Downs TM, DeWolf WC, O'Donnell MA. IFN-α 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy. Journal of Immunology (Baltimore, Md.: 1950) 1999;162(4):2399-405.
29. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guérin in the treatment of superficial bladder tumors. Journal of Urology 1976;116(2):180-3.
30. O'Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-α 2b plus low dose bacillus Calmette-Guérin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guérin alone previously failed. Journal of Urology 2001;166(4):1300-5.
31. Plna K, Hemminki K. Familial bladder cancer in the National Swedish Family Cancer Database. Journal of Urology 2001;166(6):2129-33.
32. Ploeg M, Aben KKH, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World Journal of Urology 2009;27(3):289-93.
33. Punnen SP, Chin JL, Jewett MA. Management of bacillus Calmette-Guérin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy. Canadian Journal of Urology 2003;10(2):1790-5.
34. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
35. Rizza R, Moretti F, Belardelli F. Recent advances on the immunomodulatory effects of IFN-α: implications for cancer immunotherapy and autoimmunity. Autoimmunity 2010;43(3):204-9.
36. Schenkman E, Lamm DL. Superficial bladder cancer therapy. Scientific World Journal 2004;4(Suppl 1):387-99.
37. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
38. Shang PF, Kwong J, Wang ZP, Tian J, Jiang L, Yang K, et al. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database of Systematic Reviews 2011, Issue 5. [DOI: 10.1002/14651858.CD006885.pub2]
39. Shelley M, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M. Intravesical Bacillus Calmette-Guérin in Ta and T1 bladder cancer. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD001986]
40. Shelley M, Court JB, Kynaston H, Wilt T, Coles B, Mason M. Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD003231]
41. Shelley MD, Mason MD, Kynaston H. Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treatment Reviews 2010;36(3):195-205.
42. Sobin LH, Gospodariwicz M, Wittekind C, editors. TNM classification of malignant tumors. UICC International Union Against Cancer. 7th Edition. Wiley-Blackwell, November 2009.
43. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. Journal of Urology 2004;171(6 Pt 1):2186-90.
44. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. European Urology 2006;49(3):466-77.
45. van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. European Urology 2009;56(3):430-42.
46. Vineis P, Simonato L. Proportion of lung and bladder cancers in males resulting from occupation: a systematic approach. Archives of Environmental Health 1991;46(1):6-15.
47. Whelan P. The treatment of non-muscle-invasive bladder cancer with intravesical chemotherapy and immunotherapy. European Urology Supplements 2007;6(8):568-71.
48. Zhang Y, Khoo HE, Esuvaranathan K. Effects of bacillus Calmette-Guèrin and interferon alpha-2B on cytokine production in human bladder cancer cell lines. Journal of Urology 1999;161(3):977-83.